Citations

Clear

63 citation(s) found for "Anderson, Jennifer".

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
Pilarski, Robert , Yurgelun, Matthew B. , Dickson, Patricia , Elkhanany, Ahmed , Friedman, Susan , Hutton, Mollie L., Khan, Seema, Klein, Catherine, Kohlmann, Wendy , Kurian, Allison W. , Laronga, Christine , Mak, Julie , Menendez, Carolyn S. , Merajver, Sofía D. , Norquist, Barbara S., Offit, Kenneth , Pederson, Holly J. , Reiser, Gwen , Shannon, Kristen M. , Visvanathan, Kala , Weitzel, Jeffrey N. , Wick, Myra , Wisinski, Kari B. , Dwyer, Mary A., Darlow, Susan, Norquist, Barbara M. , Wick, Myra J, Weitzel, Jeffrey N , Visvanathan, Kala , Kurian, Allison W , Norquist, Barbara , Elkhanany, Ahmed , Daly, Mary Beryl , Berry, Michael P., Buys, Saundra S. , Domchek, Susan M. , Garber, Judy E. , Goggins, Michael , Litton, Jennifer K. , Pal, Tuya

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 7, 2020 | Volume: 18 | Issue: 4 | Pages: 380-391

10.6004/jnccn.2020.0017 | PMID 32259785 Get It

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2 , pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.
Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
Pierce, Lori J. , Dietz, Jill R. , Dragun, Anthony , Gelpí, Judith Balmaña, Hofstatter, Erin , Jatoi, Ismail , Kennedy, Elaine, Mayr, Nina A. , Qamar, Rubina , Trombetta, Mark , Harvey, Brittany , Somerfield, Mark R. , Zakalik, Dana , Tung, Nadine , Boughey, Judy C. , Robson, Mark E. , Bedrosian, Isabelle , Isaacs, Claudine , Litton, Jennifer K. , Harvey, Brittany E

Mayo Clinic

Journal of Clinical Oncology | April 3, 2020 | Volume: 38 | Issue: 18 | Pages: 2080-2106

10.1200/jco.20.00299 | PMID 32243226 Get It

PURPOSE To develop recommendations for management of patients with breast cancer (BC) with germline mutations in BC susceptibility genes. METHODS The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology convened an Expert Panel to develop recommendations based on a systematic review of the literature and a formal consensus process. RESULTS Fifty-eight articles met eligibility criteria and formed the evidentiary basis for the local therapy recommendations; six randomized controlled trials of systemic therapy met eligibility criteria. RECOMMENDATIONS Patients with newly diagnosed BC and BRCA1/ 2 mutations may be considered for breast-conserving therapy (BCT), with local control of the index cancer similar to that of noncarriers. The significant risk of a contralateral BC (CBC), especially in young women, and the higher risk of new cancers in the ipsilateral breast warrant discussion of bilateral mastectomy. Patients with mutations in moderate-risk genes should be offered BCT. For women with mutations in BRCA1/ 2 or moderate-penetrance genes who are eligible for mastectomy, nipple-sparing mastectomy is a reasonable approach. There is no evidence of increased toxicity or CBC events from radiation exposure in BRCA1/ 2 carriers. Radiation therapy should not be withheld in ATM carriers. For patients with germline TP53 mutations, mastectomy is advised; radiation therapy is contraindicated except in those with significant risk of locoregional recurrence. Platinum agents are recommended versus taxanes to treat advanced BC in BRCA carriers. In the adjuvant/neoadjuvant setting, data do not support the routine addition of platinum to anthracycline- and taxane-based chemotherapy. Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/ 2 carriers. Data are insufficient to recommend PARP inhibitor use in the early setting or in moderate-penetrance carriers. Additional information available at www.asco.org/breast-cancer-guidelines .
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Keung, Emily Z. , Salazar, Ruth , Rodrigues-Canales, Jaime, Bolejack, Vanessa , Tine, Brian A. Van , Schuetze, Scott M. , Attia, Steven , Riedel, Richard F. , Hu, James , Okuno, Scott H. , Priebat, Dennis A., Movva, Sujana , Davis, Lara E. , Wang, Wei‐Lien , Wargo, Jennifer A. , Tawbi, Hussein A. , Bolejack, Vanessa , Van Tine, Brian A , Schuetze, Scott M , Riedel, Richard F , Okuno, Scott , Davis, Lara E , Reed, Damon R , Reuben, Alexandre , Lazar, Alexander J , Burgess, Melissa , Parra, Edwin Roger , Reed, Damon R. , Roland, Christina Lynn , Reinke, Denise K. , Lazar, Alexander J.

Mayo Clinic

Clinical Cancer Research | January 3, 2020 | Volume: 26 | Issue: 6 | Pages: 1258-1266

10.1158/1078-0432.ccr-19-1824 | PMID 31900276 Get It

Abstract Purpose: We recently reported a 17.5% objective RECIST 1.1 response rate in a phase II study of pembrolizumab in patients with advanced sarcoma (SARC028). The majority of responses occurred in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). We sought to determine whether we can identify immune features that correlate with clinical outcomes from tumor tissues obtained pre- and on-treatment. Patients and Methods: Pretreatment (n = 78) and 8-week on-treatment (n = 68) tumor biopsies were stained for PD-L1 and multiplex immunofluorescence panels. The density of positive cells was quantified to determine associations with anti–PD-1 response. Results: Patients that responded to pembrolizumab were more likely to have higher densities of activated T cells (CD8+ CD3+ PD-1+) and increased percentage of tumor-associated macrophages (TAM) expressing PD-L1 pre-treatment compared with non-responders. Pre-treatment tumors from responders also exhibited higher densities of effector memory cytotoxic T cells and regulatory T cells compared with non-responders. In addition, higher density of cytotoxic tumor-infiltrating T cells at baseline correlated with a better progression-free survival (PFS). Conclusions: We show that quantitative assessments of CD8+ CD3+ PD-1+ T cells, percentage of TAMs expressing PD-L1, and other T-cell densities correlate with sarcoma response to pembrolizumab and improved PFS. Our findings support that multiple cell types present at the start of treatment may enhance tumor regression following anti–PD-1 therapy in specific advanced sarcomas. Efforts to confirm the activity of pembrolizumab in an expansion cohort of patients with UPS/DDLPS are underway.
Abstract 385: MTAP gene deficiency creates vulnerability to anti-folate therapy in urothelial bladder carcinoma
Wang, Wei‐Lien , Zhang, Xin-Qiao, Song, Jian H. , López, Lidia, Ramachandran, Sumankalai , Hoang, Anh , Garnett, Tyrone, Tu, Shi‐Ming, Gallick, Gary E., Efstathiou, Eleni , Benedict, William F., Chen, Jianfeng , Alhalabi, Omar , Han, Guangchun , Campbell, Matthew T. , Shah, Amishi Yogesh , Wang, Jennifer Rui , Siefker-Radtke, Arlene Odelia , Tu, Shi‐Ming , Titus, Mark Anton , Guo, Charles Chuanhai , Logothetis, Christopher J. , Ho, Thai H. , Wang, Linghua , Gao, Jianjun

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 385-385

10.1158/1538-7445.am2019-385 Get It

Abstract Background: The methylthioadenosine phosphorylase (MTAP) gene encodes an essential enzyme for the salvage pathway of adenosine synthesis and is frequently lost in different types of cancer including urothelial bladder carcinoma. Therefore, MTAP-deficient tumors are theoretically very sensitive to anti-folate agents such as pemetrexed that can effectively block the de novo pathway of adenosine synthesis and as a result, create a state of synthetic lethality. We thus hypothesize that tumor MTAP gene deficiency is associated with response to pemetrexed therapy in bladder cancer. Methods: In this study, we investigated MTAP gene deficiency rates in the TCGA database and confirmed MTAP protein loss by immunohistochemistry using a tumor tissue microarray containing bladder tumor tissues from 151 patients. We then performed in vitro and in vivo studies using MTAP-proficient and MTAP-deficient human bladder cancer cell lines. Functional loss of MTAP was verified with mass spectrometry, which detects its substrate methylthioadenosine (MTA) levels. We also correlated these pre-clinical studies with clinical response data on patients with metastatic bladder cancer treated with pemetrexed. Results: We identified that 27.8% bladder cancer patients have MTAP protein deficiency, which is consistent with exome sequencing data from the TCGA database. In vitro data showed MTAP-deficient human bladder cancer cell lines were significantly more sensitive to pemetrexed, with IC50 at least 40 times lower than MTAP-proficient cell lines. Subsequent knockdown of the MTAP gene in MTAP-proficient cell lines increased sensitivities to pemetrexed treatment. Consistent with the in vitro data, pemetrexed significantly inhibited the growth of MTAP-deficient or knockdown xenograft tumors but not MTAP-proficient tumors. Furthermore, 4 of 4 (100%) patients with MTAP-deficient metastatic bladder cancer responded to pemetrexed treatment, whereas only 1 of 11 (9%) patients with MTAP-proficient metastatic bladder cancer responded to pemetrexed. Conclusion: Our data demonstrate that MTAP gene loss in urothelial bladder cancer leads to a metabolic state of synthetic lethality with pemetrexed therapy. Therefore, bladder tumor MTAP loss should be further investigated as a potential biomarker for selection of patients for anti-folate therapy. Citation Format: Jianfeng Chen, Omar Alhalabi, Guangchun Han, Wei-Lien Wang, Xin-Qiao Zhang, Jian H. Song, Lidia P. Lopez, Sumankalai Ramachandran, Anh G. Hoang, Tyrone Garnett, Matthew Campbell, Amishi Y. Shah, Jennifer Wang, Arlene O. Siefker-Radtke, Shi-Ming Tu, Mark Titus, Charles C. Guo, Gary E. Gallick, Eleni Efstathiou, William F. Benedict, Christopher J. Logothetis, Thai H. Ho, Linghua Wang, Jianjun Gao. MTAP gene deficiency creates vulnerability to anti-folate therapy in urothelial bladder carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 385.
Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis.
Zurita, Amado J. , Chapin, Brian F. , Harris, Deborah , Pisters, Louis L. , Araujo, John C. , Pettaway, Curtis A. , Tu, Shi‐Ming, Papadopoulos, John, Wang, Jennifer , Pagliaro, Lance C. , Davis, John W. , Tidwell, Rebecca S. , Troncoso, Patricia , Aparicio, Ana M , Tu, Shi‐Ming , Logothetis, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 5078-5078

10.1200/jco.2019.37.15_suppl.5078 Get It

5078 Background: Strategies integrating androgen targeted and locoregional therapies are being increasingly used in PCa with regional spread, but are rarely curative. Angiogenesis inhibitors delay progression in castration resistant PCa and may synergize with ADT through endothelial cell apoptosis in hormone naïve patients (pts). We hypothesized that the frontline combination of ADT with the potent VEGF inhibitor Axi would improve PCa control relative to ADT alone and allow for meaningful time off systemic therapy after surgical consolidation. Methods: Pts with either clinically detected LN+ (TxN1M0 or TxNxM1a) or very high risk for LN PCa were treated with ADT for 2 mos and then randomized 2:1 to respectively add open label Axi (5 mg PO bid) vs. continue ADT alone for 4 mos until surgery. Those responding with PSA ≤5 ng/mL were offered prostatectomy and extended pelvic lymphadenectomy (RP). ADT +/- Axi was withheld postoperatively and PSA measured q3 mos until 1 y. Primary objective: proportion of pts progression free (FFP) 12 mos after RP, defined as PSA ≤1.0 ng/mL and no radiation or ADT, aiming to detect a 35% difference favoring ADT+Axi. Results: 72 pts completed accrual. We report on the 54 pts with LN+ disease: median age 62 y (range 42-76), pretreatment PSA 22.9 ng/mL (range 3.6 - 404.4), 38 N1 / 16 M1a. Table shows presurgical therapy outcomes. Path responses in the prostate were similar between arms, but in 5 ADT+Axi vs. 0 ADT LN+ pts there was no residual nodal disease. Testosterone recovery: 24/26 ADT+Axi and 9/9 ADT RP pts by 6 mos. 21/36 ADT+Axi and 15/18 ADT pts have failed; 1 y FFP estimates 48.0% (SE 8.6%) and 16.7% (SE 8.3%), respectively (p = 0.02). 1 y undetectable PSA 9 pts (6 ADT+Axi). No grade 4 toxicities or unexpected side-effects were observed. Conclusions: 1 year after RP, ADT+Axi resulted in proportionally greater number of LN+ PCa pts off treatment and progression free than ADT alone. Tissue analysis is evaluating predictors of benefit to further develop angiogenesis inhibition as part of combination strategies for hormone naïve PCa. Clinical trial information: NCT01409200. [Table: see text]
Frequency and predictors of the potential overprescribing of antidepressants in elderly residents of a geographically defined U.S. population
Bobo, William V. , Leung, Jonathan G. , Stoppel, Cynthia , Hoel, Robert W. , Chang, Zheng , Lachner, Christian , Chauhan, Mohit , Flowers, L, Brue, Scott M., Frye, Mark A. , Sauver, Jennifer L. St. , Rocca, Walter A. , Sutor, Bruce, Grossardt, Brandon R. , Takahashi, Paul Y. , Flowers, Lee, St Sauver, Jennifer, Leung, Jonathan G , V Bobo, William , St Sauver, Jennifer L , Lapid, Maria I. , Chauhan, Mohit

Mayo Clinic

Pharmacology Research & Perspectives | January 24, 2019 | Volume: 7 | Issue: 1 | Pages: No page available

10.1002/prp2.461 | PMID 30693088 Get It

AbstractThe purpose of this study was to estimate the extent of potential antidepressant overprescribing in a geographically defined U.S. population, and to determine the indications and factors that account for it. We conducted a cohort study of new antidepressant prescriptions for elderly residents of Olmsted County, Minnesota, 2005‐2012, using the Rochester Epidemiology Project medical records‐linkage system. Indications for antidepressants were abstracted from health records for all cohort members. Potential antidepressant overprescribing was defined based on regulatory approval, the level of evidence identified from a standardized drug information database, and multidisciplinary expert review. Predictors of potential antidepressant overprescribing were investigated using logistic regression models, stratified by general antidepressant indication (general medical indication, specific psychiatric diagnosis, and non‐specific psychiatric symptoms). Potential antidepressant overprescribing occurred in 24% of 3199 incident antidepressant prescriptions during the study period, and involved primarily newer antidepressants that were prescribed for non‐specific psychiatric symptoms and subthreshold diagnoses. Potential antidepressant overprescribing was associated with nursing home residence, having a higher number of comorbid medical conditions and outpatient prescribers, taking more concomitant medications, having greater use of urgent or acute care services in the year preceding the index antidepressant prescription, and being prescribed antidepressants via telephone, e‐mail, or patient portal. In conclusion, potential antidepressant overprescribing occurred in elderly persons and involved mainly newer antidepressants used for non‐specific psychiatric symptoms and subthreshold diagnoses, and was associated with indicators of higher clinical complexity or severity and with prescribing without face‐to‐face patient contact.
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
Gerson, James N. , Villa, Diego , Gerrie, Alina S. , Chapani, Parv , Medeiros, L. Jeffrey , Wang, Michael I., Cohen, Jonathon B. , Calzada, Oscar , Churnetski, Michael C. , Hill, Brian T. , Sawalha, Yazeed , Hernandez‐Ilizaliturri, Francisco J. , Kothari, Shalin , Bast, Martin, Fenske, Timothy S. , Gari, Swapna Narayana Rao, Maddocks, Kami J. , Bond, David A. , Bachanová, Veronika , Kolla, Bhaskar , Lansigan, Frederick , Donovan, Alexandra M., Wagner‐Johnston, Nina D. , Messmer, Marcus , Anderson, Jennifer K., Reddy, Nishitha , Kovach, Alexandra E. , Glenn, Martha, Inwards, David J. , Karmali, Reem , Kaplan, Jason , Rajguru, Saurabh, Evens, Andrew M. , Klein, Andreas K. , Umyarova, Elvira , Pulluri, Bhargavi , Amengual, Jennifer E. , Diefenbach, Catherine , Fisher, Richard I., Bachanova, Veronika , Sawalha, Yazeed , Gerrie, Alina S , Evens, Andrew M , Karmali, Reem , Bond, David A , Medeiros, L Jeffrey , Lansigan, Frederick , Diefenbach, Catherine S , Kovach, Alexandra E , Handorf, Elizabeth A. , Li, Shaoying , Vose, Julie M. , Chavez, Julio C , Shah, Bijal , Burns, Timothy Francis , Mehta, Amitkumar , Landsburg, Daniel J. , Caimi, Paolo F. , Lue, Jennifer Kimberly , Barta, Stefan K

Mayo Clinic

Journal of Clinical Oncology | January 7, 2019 | Volume: 37 | Issue: 6 | Pages: 471-480

10.1200/jco.18.00690 | PMID 30615550 Get It

PURPOSE Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. PATIENTS AND METHODS We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score–weighted (PSW) analysis were performed. RESULTS Data were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2). CONCLUSION In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.
Breast cancer in adolescents and young adults
Johnson, Rebecca H. , Anders, Carey K. , Ruddy, Kathryn J. , Bleyer, Archie , Bleyer, Archie , Litton, Jennifer K.

Mayo Clinic

Pediatric Blood & Cancer | August 30, 2018 | Volume: 65 | Issue: 12 | Pages: No page available

10.1002/pbc.27397 | PMID 30156052 Get It

AbstractBreast cancer is the most common cancer of adolescents and young adult (AYA) women aged 15 to 39 years, accounting for 5.6% of all invasive breast cancer in women. In comparison with older women, AYAs are more likely to have familial cancer predisposition genes, larger breast tumors, unfavorable biological characteristics, distant metastatic disease at diagnosis, and adverse outcome. Endocrine therapy and some chemotherapy recommendations differ between young and older women. AYAs require coordinated multidisciplinary care, treatment regimens that minimize late effects such as premature menopause and osteoporosis, and proactive management of psychological and sexual health during and after cancer treatment.
Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors
Phan, Jack , Pollard, Courtney , Brown, Paul D. , Guha‐Thakurta, Nandita , Garden, Adam S. , Fuller, Clifton D. , Frank, Steven J. , Gunn, G. Brandon , Morrison, William H. , Ho, Jennifer , Li, Jing , Ghia, Amol J. , Yang, James N., Luo, Dershan , Wang, He C., Su, Shirley Y. , Raza, Shaan M. , Gidley, Paul W. , Hanna, Ehab Y., Rosenthal, David I. , Hanna, Ehab Y. , DeMonte, Franco , Phan, Jack , Su, Shirley Y , Fuller, Clifton David

Mayo Clinic

Journal of Neurosurgery | April 27, 2018 | Volume: 130 | Issue: 3 | Pages: 812-821

10.3171/2017.11.jns172084 | PMID 29701557 Get It

OBJECTIVEThe objective of this study was to assess outcomes after Gamma Knife radiosurgery (GKRS) re-irradiation for palliation of patients with trigeminal pain secondary to recurrent malignant skull base tumors.METHODSFrom 2009 to 2016, 26 patients who had previously undergone radiation treatment to the head and neck received GKRS for palliation of trigeminal neuropathic pain secondary to recurrence of malignant skull base tumors. Twenty-two patients received single-fraction GKRS to a median dose of 17 Gy (range 15–20 Gy) prescribed to the 50% isodose line (range 43%–55%). Four patients received fractionated Gamma Knife Extend therapy to a median dose of 24 Gy in 3 fractions (range 21–27 Gy) prescribed to the 50% isodose line (range 45%–50%). Those with at least a 3-month follow-up were assessed for symptom palliation. Self-reported pain was evaluated by the numeric rating scale (NRS) and MD Anderson Symptom Inventory–Head and Neck (MDASI-HN) pain score. Frequency of as-needed (PRN) analgesic use and opioid requirement were also assessed. Baseline opioid dose was reported as a fentanyl-equivalent dose (FED) and PRN for breakthrough pain use as oral morphine-equivalent dose (OMED). The chi-square and Student t-tests were used to determine differences before and after GKRS.RESULTSSeven patients (29%) were excluded due to local disease progression. Two experienced progression at the first follow-up, and 5 had local recurrence from disease outside the GKRS volume. Nineteen patients were assessed for symptom palliation with a median follow-up duration of 10.4 months (range 3.0–34.4 months). At 3 months after GKRS, the NRS scores (n = 19) decreased from 4.65 ± 3.45 to 1.47 ± 2.11 (p < 0.001); MDASI-HN pain scores (n = 13) decreased from 5.02 ± 1.68 to 2.02 ± 1.54 (p < 0.01); scheduled FED (n = 19) decreased from 62.4 ± 102.1 to 27.9 ± 45.5 mcg/hr (p < 0.01); PRN OMED (n = 19) decreased from 43.9 ± 77.5 to 10.9 ± 20.8 mg/day (p = 0.02); and frequency of any PRN analgesic use (n = 19) decreased from 0.49 ± 0.55 to 1.33 ± 0.90 per day (p = 0.08). At 6 months after GKRS, 9 (56%) of 16 patients reported being pain free (NRS score 0), with 6 (67%) of the 9 being both pain free and not requiring analgesic medications. One patient treated early in our experience developed a temporary increase in trigeminal pain 3–4 days after GKRS requiring hospitalization. All subsequently treated patients were given a single dose of intravenous steroids immediately after GKRS followed by a 2–3-week oral steroid taper. No further cases of increased or new pain after treatment were observed after this intervention.CONCLUSIONSGKRS for palliation of trigeminal pain secondary to recurrent malignant skull base tumors demonstrated a significant decrease in patient-reported pain and opioid requirement. Additional patients and a longer follow-up duration are needed to assess durability of symptom relief and local control.
Association of Long-term Opioid Therapy With Functional Status, Adverse Outcomes, and Mortality Among Patients With Polyneuropathy
Hoffman, E. Matthew , Watson, James C. , Sauver, Jennifer L. St. , Staff, Nathan P. , Klein, Christopher J. , St Sauver, Jennifer, Staff, Nathan P , Klein, Christopher J , St Sauver, Jennifer L

Mayo Clinic

JAMA Neurology | May 22, 2017 | Volume: 74 | Issue: 7 | Pages: 773

10.1001/jamaneurol.2017.0486 | PMID 28531306 Get It